CAMP4 Therapeutics Corporation Operating Lease, Right-of-Use Asset, Amortization Expense
CAMP4 Therapeutics Corporation (CAMP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $96.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- CAMP4 Therapeutics Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $62.00K, a 87.06% decline year-over-year.
- CAMP4 Therapeutics Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $34.00K, a 92.84% decline year-over-year.
- CAMP4 Therapeutics Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $480.00K, a 3.45% increase year-over-year.
- CAMP4 Therapeutics Corporation operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $489.00K, a 8.67% increase year-over-year.
- CAMP4 Therapeutics Corporation operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.92M, a 9.95% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.75M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $96.00K 10-Q · filed 2026-08-13 | $576.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $34.00K 10-Q · filed 2026-05-07 | $514.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.00M derived: sum of 3 quarters · filed 2026-05-07 | $1.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $969.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.45M derived: sum of 3 quarters · filed 2026-08-13 | $1.92M 10-K · filed 2026-03-05 |
| 2025-09-30 | $489.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $968.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.44M 10-Q · filed 2025-11-06 | $1.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $479.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $954.00K 10-Q · filed 2026-08-13 | $1.42M derived: sum of 3 quarters · filed 2026-08-13 | $1.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $475.00K 10-Q · filed 2026-05-07 | $939.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.39M derived: sum of 3 quarters · filed 2026-05-07 | $1.82M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $464.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $914.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.35M derived: sum of 3 quarters · filed 2026-03-05 | $1.75M 10-K · filed 2026-03-05 |
| 2024-09-30 | $450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $882.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.28M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $835.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $403.00K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |